SCHEDULE: Vanguard Discloses 5% Stake in Keros Therapeutics

The Vanguard Group has reported a 5% beneficial ownership stake in Keros Therapeutics Inc., holding 1,525,355 shares of common stock.

Summary

• The Vanguard Group reported a 5% beneficial ownership stake in Keros Therapeutics Inc.
• This ownership amounts to 1,525,355 shares of common stock, representing 5% of the class.
• The filing date for this Schedule 13G/A was January 30, 2026, reflecting ownership as of December 31, 2025.
• Vanguard holds shared voting power over 146,965 shares and shared dispositive power over all 1,525,355 shares.
• An internal realignment at The Vanguard Group, Inc. on January 12, 2026, means its subsidiaries will now report beneficial ownership separately.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a major institutional investor like Vanguard can imply a degree of confidence in the company's long-term viability, even if it's a passive investment.

Positives

• A major institutional investor like The Vanguard Group holding a 5% stake can signal confidence in Keros Therapeutics Inc.'s long-term prospects.
• The investment is held in the ordinary course of business, indicating a passive investment strategy rather than an activist one.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like The Vanguard Group is a common feature in publicly traded companies, especially in sectors like biotechnology where long-term investment horizons are often considered. Vanguard's passive investment strategies typically involve holding broad market indices, which would include Keros Therapeutics if it's part of such an index. This filing reflects a routine disclosure of a significant, but passive, stake.

Comparison to Industry Standards

• Vanguard's 5% stake in Keros Therapeutics Inc. is a standard disclosure for institutional investors crossing the 5% beneficial ownership threshold, as mandated by SEC regulations.
• This level of ownership is typical for large index funds or actively managed funds within a diversified portfolio, similar to holdings disclosed by other major asset managers like BlackRock.
• This is not an activist stake, which would typically be disclosed via a Schedule 13D and involve a stated intent to influence management or control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Vanguard may provide a sense of stability and validation for existing shareholders.
• Management: Management of Keros Therapeutics Inc. will be aware of a large, passive institutional holder, which typically implies a focus on long-term value creation.

Next Steps

• The Vanguard Group's subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following the internal realignment on January 12, 2026.

Key Dates

Recommendation

The filing indicates a significant, passive investment by The Vanguard Group, a major institutional investor. While this signals a degree of confidence, it is a routine disclosure for a large asset manager and does not provide new fundamental information about Keros Therapeutics Inc.'s operational performance or strategic direction. Therefore, a 'hold' recommendation is appropriate, pending further analysis of the company's financial results and business developments.

Keywords

Keros Therapeutics Inc, Vanguard Group, Institutional Ownership, Common Stock, Beneficial Ownership, Schedule 13G, Investment Adviser, Biotechnology